Nutex Health Inc. (NUTX) — RQD Stock Rating Cockpit

Per the Roarable RQD rating, NUTX scores 86 out of 100, graded A, with the verdict label "Roarable Strong Buy — Excellent Cash & Whale Support." The five pillars are:

• Fundamental Cash Engine (19/20): The rating cites ROIC of 85% and an FCF yield of 17.07%. For an investor, this is the strongest pillar, indicating high reported returns on invested capital and substantial free cash generation relative to the share price. The FCF yield also implies the market is pricing the stock at a steep discount to its cash output, which is an upside driver if the cash figures persist, though it may reflect skepticism about sustainability.
• Whale 13F Flow (14/20): The rating references institutional accumulation and options positioning. This is a moderate score; institutional interest is present but less decisive than the fundamental pillars. No holder-level detail is supplied in the source data to verify the magnitude.
• Insider Conviction (19/20): Per the rating, SEC Form 4 and Congressional PTR cluster flow is strong. High scores here suggest insiders are net-positioned favorably, a conviction signal, though the underlying transaction records are not provided in this dossier.
• Macro Regime Fit (18/20): The rating cites a beta of 1.0 and sector sensitivity. A beta of 1.0 means the stock is expected to move in line with the broader market, so it offers neither defensive insulation nor amplified volatility relative to the market.
• Forensic Balance Sheet (16/20): The rating cites an Altman Z of 3.75, a Piotroski F of 9/9, and Debt/Equity of 0.09. These figures point to low leverage and strong financial-health screens, the lowest-weighted pillar here, which is consistent with a healthy but not flawless balance sheet.

Investor implications: the rating's strength rests mainly on cash-generation metrics and low leverage. The tradeoffs to weigh are that the stock trades at a P/E (TTM) of 20.3 and EV/EBITDA of 4.6, the price sits 1.19% lower on the session, and its 52-week range ($83.99–$226.16) shows wide price dispersion. The RQD is a scoring framework and does not constitute a recommendation.

Nutex Health Inc. (NUTX) is a NASDAQ-listed company classified in the Consumer Discretionary sector and Business Services industry, per the profile. Not available in source data for detailed product lines, customer base, or revenue-generation model.

Per the SEC financials, revenue rose from $247.6M in FY 2023 to $875.3M in FY 2025, and operating income moved from $-31.8M to $275.6M over the same span. Per the market data, the gross margin is 50.8%, operating margin 31.5%, and net margin 8.1%, with ROIC at 85%. Per the Roarable RQD rating, the Altman Z-Score is 3.75 and the Piotroski F-Score is 9/9. Debt/Equity is 0.09 per the rating. The net margin is notably thinner than the operating margin, which the source data does not explain.

Per the recent news feed, the items are:

• Motley Fool ("2 Stocks to Buy Hand Over Fist in October"): Market wire, yellow light; a general market-action piece.
• TradingView (Estimates): Market wire, yellow light; estimates coverage, with no figures given in the source.
• NAI500 ("These Two Healthcare Stocks Are Beating the Sector, They Still Look Cheap"): Catalyst, green light.
• Stock Titan: Notes that Nutex Health will discuss its results at 9:30 a.m. Central time on Nov. 6; market wire, yellow light. This is the one dated event in the feed.
• Simply Wall St ("Could Be 25% Undervalued On Solid Results And Raised Targets"): Catalyst, green light.
• marketscreener.com (Ladenburg Thalmann initiation): Market wire, yellow light; the headline references a Buy rating and a $336 price target.

Risk watch items: the price target in the Ladenburg headline ($336) is above the 52-week high of $226.16 and above the current price, but this is noted from the headline only and not verified against analyst data. Proprietary signals in the Butterfly graph: none. Supply chain: NONE.

Analyst data: Not available in source data (analyst_data is NONE). Holder data, including Form 4, 13F, and Congressional trades: Not available in source data (holders is NONE). The Ladenburg Thalmann headline referenced in the news feed states a Buy rating and $336 price target, but this is not corroborated by the analyst data section.

• Why does net margin (8.1%) sit so far below operating margin (31.5%), and what drives the gap?
• Is the FY 2025 FCF of $245.6M recurring, given FY 2024 FCF was $20.8M?
• What do the FY 2025 and FY 2024 EPS figures look like, since both are reported as N/A?
• Who are the holders and what are the magnitudes of the 13F and insider positions behind the pillar scores?
• Does the $336 price target in the Ladenburg headline reflect a current, verifiable analyst view?